I think this shows that the productive life for Viracept is unknown, and that in fact it may be for several years, I remembered last year when the Crosson fiasco, that this guy lowered AGPH because of questions with the life for Viracept. How wrong he was. (Or maybe right for his own interests).
======================================================================
<To: David S. (2325 )
From: Oliver & Co Wednesday, Oct 15 1997 12:14AM ET
Reply # of 5350
Maybe, it's just that the timing of everything makes me wonder. Specially when you look at the data. Correct me if I am wrong, but wasn't Crosson the only analyst to lower the rating on the stock?, and based on what?. This man is looking at the projected revenue of Viracept to the year 2002. I treat HIV, and I am sure that by then there will be many more drugs, superior to Nelf, and Cryx. I did not invest in AGPH only because of Nelf., but because of their pipeline.
I do not think that we can expect any of these drugs to have a highly productive life of more than 2-3 years, because that is how fast the field is changing. And with Fast Track, drugs should be comming out earlier.
I would love to think that the market is 100% clean. Maybe it is. I do not know Mr. Crosson myself. It's just the timing of it all.
Just a thought...>
|
